CardioQ Update

RNS Number : 5947C

Deltex Medical Group PLC

03 September 2008

 



Deltex Medical Group plc

TURP syndrome case study published

3 September 2008 - Deltex Medical Group plc ('Deltex Medical' or the 'Company'), the UK's leading haemodynamic monitoring company, notes the publication of the first clinical case study to document using its CardioQ-ODM product to detect and treat TURP syndrome.

A growing number of doctors are already starting to use the CardioQ-ODM to guide fluid management in urology surgery as well as other types of major surgery. The CardioQ-ODM's ability, demonstrated by this case study, to help identify and treat a serious complication specifically associated with a common urology operation is expected to further strengthen the already compelling case for using it on all major urology cases.

Transurethral resection of the prostate (TURP) is a surgical procedure in which some of the male enlarged prostate gland is removed to enable urine to flow more freely. This is a common procedure, with around about 40,000 operations performed in the UK each year. When this procedure is required to be conducted under general aesthetic, a significant minority of patients can suffer TURP syndrome as a result of the procedure. TURP syndrome occurs when too much of the fluid used to flush out the bladder during surgery is absorbed by the body. This can cause serious complications affecting the cardiovascular system which may, in certain circumstances, be fatal.

In the September issue of the journal 'Anesthesia and Analgesia', doctors from the University Medical Center in Amsterdam report how by using the CardioQ-ODM on a routine basis in major surgery they were able to identify TURP syndrome during surgery on a 75 year-old patient. The onset of TURP syndrome was identified in its early stages through marked increases in each of the measured variables of stroke volume, mean acceleration, peak velocity and corrected flow time. The latter three measurements are unique to oesophageal Doppler monitoring (ODM). Because ODM is unique in directly measuring blood flows, it is the only technology able to detect small changes in stroke volume quickly and reliably.

Having identified the onset of TURP syndrome, the doctors were able to treat it using the CardioQ-ODM both for the remainder of the surgical procedure and afterwards in a critical care unit including for four hours after the patient had fully regained consciousness. As a result the patient was able to go home on the second day after surgery.

Deltex Medical's Chief Executive, Andy Hill commented:

'This case study is important as it demonstrates clearly the ability of ODM to allow doctors to detect and treat haemodynamic changes early. Over the coming months, we expect to see growing amounts of clinical data showing the benefits of CardioQ-ODM specifically in urological surgery.'

For further information, please contact:-

Deltex Medical Group plc            01243 774 837

Nigel Keen, Chairman                    [e-mail]

Andy Hill, Chief Executive              [e-mail]

Ewan Phillips, Finance Director      [e-mail] 

Gavin Anderson & Company       0207 554 1400

Deborah Walter                             [e-mail]

Robert Speed                                [e-mail]

Stuart Macaulay                            [e-mail] 

Nominated Adviser & Broker

Charles Stanley Securities          020 7149 6000

Philip Davies                                 [e-mail] 

Russell Cook                                [e-mail] 

  Notes for Editors

Deltex Medical manufactures and markets the CardioQ-ODM™ monitor, which uses disposable ultra-sound probes inserted into the oesophagus to determine the amount of blood being pumped around the body - 'circulating blood volume'. Reduced circulating blood volume is known as hypovolaemia, which leads to insufficient oxygen being delivered to the organs. This causes medical complications including peripheral and major organ failure which can lead to death. Hypovolaemia, which is akin to severe dehydration, affects virtually every patient having surgery because of the combined effects of pre-operative starvation, the impact of the anaesthetic agents and trauma from the surgery itself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise the amount of circulating blood significantly reduces post-operative complications allowing patients to make a faster, more complete recovery and return home earlier.

The CardioQ-ODM incorporates the Company's proprietary software and a small diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is used for transmitting and receiving an ultra-sound signal. By using this technology, the CardioQ-ODM provides clinicians with the ability to haemodynamically optimise critically ill patients and those undergoing routine moderate to major surgery through the controlled administration of fluid and drugs. Haemodynamic optimisation has been scientifically proven to improve the speed and quality of patient recovery and reduce hospital stay.

There are already over 1,500 CardioQ-ODMs currently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. In addition, there are currently more than 100 clinical publications on the use of the CardioQ-ODM which have repeatedly:-

• Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works

• Proved that the CardioQ-ODM works in a wide range of surgical procedures

• Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients.

The SupraQ™ is an entirely non-invasive device which uses an ultrasound probe held at the base of the patient's neck to track the flow of blood in the aorta; it presents the same data as the CardioQ-ODM in a similar format and is used for taking snapshots or monitoring over short periods.

 

END

 

 

NRAFKBKDOBKDDCK